Truist lowered the firm’s price target on Teleflex (TFX) to $149 from $200 and keeps a Hold rating on the shares. The firm says the company’s ...

Teleflex's business units, including urology and acute care will come under NewCo, with interventional and surgical under ...

Teleflex, whose shares sank nearly 20% Thursday, will acquire most of Biotronik’s vascular intervention assets. Teleflex also ...

Teleflex Inc. closed 44.33% below its 52-week high of $249.91, which the company reached on September 27th.

Teleflex Incorporated TFX posted fourth-quarter 2024 adjusted earnings per share (EPS) from continuing operations of $3.89, ...

Learn more about whether LeMaitre Vascular, Inc. or Teleflex Incorporated is a better investment based on AAII's A+ Investor ...

Teleflex to separate into two companies by mid-2026 and acquire Biotronik's Vascular Intervention unit for €760 million. CFO ...

Teleflex (NYSE: TFX) announced today that it plans to separate its Urology, Acute Care and OEM businesses into a new publicly ...

Piper Sandler analyst Matt O’Brien downgraded Teleflex (TFX) to Neutral from Overweight with a price target of $140, down from $255. The ...

Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...

Teleflex shares tumbled to a 52-week low on Thursday after the medical-technology company posted disappointing financial guidance and unveiled plans for a nearly $800 million acquisition and a spinoff ...

Full Year 2024 Results Key Financial Results Revenue: US$3.05b (up 2.4% from FY 2023).